Efomycin G and it's use as yield promoter in animals
    49.
    发明授权
    Efomycin G and it's use as yield promoter in animals 失效
    Efomycin G,它用作动物的产量促进剂

    公开(公告)号:US4927810A

    公开(公告)日:1990-05-22

    申请号:US22915

    申请日:1987-03-06

    摘要: An animal growth promoter, efomycin G, is obtained by culturing Streptomycetes strain BS 1261. Efomycin G has the following properties:(a) The empirical formula: C.sub.53 H.sub.86 O.sub.18(b) The mass spectrum (fast atom bombardment) Molecular weight+Na.sup.+ : 1033(c) The .sup.1 H-nuclear magnetic resonance spectrum, stated in parts per million, shown in FIG. 1.(d) The .sup.13 C-nuclear magnetic resonance spectrum, stated in parts per million shown in FIG. 2, with chemical shifts of the CC-NMR signals as follows:______________________________________ 170.0 77.9 65.9 32.9 7.0 145.4 73.4 48.5 19.4 144.7 71.2 43.6 19.1 131.9 70.6 41.9 16.8 121.1 70.1 41.1 16.7 99.6 69.9 38.8 15.1 99.5 66.9 38.5 13.4 93.6 66.5 36.2 9.0 93.3 66.4 33.0 8.9 ______________________________________ (ppm values are relative to tetramethylsilane at 0 ppm) (e) A UV absorption maximum at 251-254 nm in methanolic solution(f) The structure according to FIG. 3.

    摘要翻译: 通过培养链霉菌菌株BS1261获得动物生长促进剂efomycin G。Efomycin G具有以下性质:(a)经验式:C53H86O18(b)质谱(快速原子轰击)分子量+ Na +:1033( c)1H-核磁共振谱,以百万分之几表示,如图1所示。 (d)13C-核磁共振谱,以图1所示的百万分之几表示。 2,CC-NMR信号的化学位移如下:-170.0 77.9 65.9 32.9 7.0 -145.4 73.4 48.5 19.4 -144.7 71.2 43.6 19.1 -131.9 70.6 41.9 16.8 -121.1 70.1 41.1 16.7 -99.6 69.9 38.8 15.1 -99.5 66.9 38.5 13.4 -93.6 66.5 36.2 9.0 -93.3 66.4 33.0 8.9 - (ppm值相对于四甲基硅烷在0ppm) - (e)在甲醇溶液中在251-254nm处的UV吸收最大值(f)根据图1的结构。 3。

    Novel use of imidazotriazinones
    50.
    发明申请
    Novel use of imidazotriazinones 审中-公开
    新型使用咪唑并三嗪酮

    公开(公告)号:US20080096880A1

    公开(公告)日:2008-04-24

    申请号:US10519129

    申请日:2003-06-24

    CPC分类号: A61K31/53

    摘要: The invention relates to novel uses of imidazo[1,2,4]triazinones for producing a medicament for the treatment and/or prophylaxis of coronary cardiopathy, heart failure, pulmonary hypertension, bladder complaints, prostatic hyperplasia, nitrate-induced tolerance, or diseases of the eye, such as glaucoma, for the treatment or prophylaxis of central, retinal or posterior ciliary artery occlusion, central retinal vein occlusion, optical neuropathy, such as anterior ischaemic optical neuropathy and glaucomatous optical neuropathy, in addition to macular degeneration, diabetes, in particular diabetic gastroparesis, for the treatment of dysperistalsis of the stomach and oesophagus, female infertility, premature contractions, pre-eclampsia, alopecia, psoriasis associated with renal syndrome, cystic fibrosis, cancer and for improving cognition, powers of concentration, learning skills or hypermnesia, in particular if the disorder is a symptom of dementia.

    摘要翻译: 本发明涉及咪唑并[1,2,4]三嗪酮在制备用于治疗和/或预防冠状动脉心脏病,心力衰竭,肺动脉高压,膀胱反应,前列腺增生,硝酸盐诱导的耐受或疾病的药物中的新用途 的眼睛,如青光眼,用于治疗或预防中枢,视网膜或后睫状动脉闭塞,视网膜中央静脉阻塞,光学神经病变,如前部缺血性视神经病变和青光眼性视神经病变,以及黄斑变性,糖尿病, 特别是糖尿病性胃轻瘫,用于治疗胃和食道的dysperistalsis,女性不孕症,早产,先兆子痫,脱发,与肾综合征相关的牛皮癣,囊性纤维化,癌症和改善认知,集中力,学习技能或 特别是如果该疾病是痴呆的症状。